Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
1. A method of treating a patient suffering from a cancer, comprising (i) identifying the patient as being likely to benefit from inhibition of the ATR/CHEK1 pathway by a method comprising:
(a) identifying an 11q deletion in a patient sample considered to be representative of the cancer, and
(b) identifying, in the patient sample, overexpression of a gene selected from the group consisting of ATR, CHEK1, CCND1, or a combination thereof,
wherein an 11q deletion and overexpression of ATR, CHEK1, CCND1, or a combination thereof, indicates that the cancer is likely to benefit from inhibition of the ATR/CHEK1 pathway; and
(ii) treating the patient with an inhibitor of the ATR/CHEK1 pathway.
2. The method of claim 1 where the patient is suffering from a cancer selected from the group consisting of squamous cell carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, multiple myeloma, and prostate cancer.
3. The method of claim 2 where the patient is suffering from an oral squamous cell carcinoma.
4. The method of claim 1 , wherein overexpression of ATR is identified.
5. The method of claim 1 , wherein overexpression of CHEK1 is identified.
6. The method of claim 1 , wherein overexpression of CCND1 is identified.
7. The method of claim 1 , wherein a nucleic acid probe representing a gene or non-coding sequence located on 11q is used to identify an 11q deletion.
8. The method of claim 1 , wherein FISH is used to identify an 11q deletion.